Oncotarget

Case Reports:

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed

Lai Wei, Lizhi Wang, Ziye Liu, Meiyi Wang, Weili Lu, Dewei Zhao, Bin Yang, Xuejun Kong, Yan Ding and Zhiqiang Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57898-57904. https://doi.org/10.18632/oncotarget.19649

Metrics: PDF 1777 views  |   HTML 2321 views  |   ?  


Abstract

Lai Wei1,*, Lizhi Wang1,*, Ziye Liu1, Meiyi Wang1, Weili Lu1, Dewei Zhao2, Bin Yang2, Xuejun Kong3, Yan Ding2,3,4 and Zhiqiang Wang1

1 Department of Otolaryngology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

2 The Institute for Translational Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

3 Department of Pediatrics, Children’s Hospital of Boston, Harvard Medical School, Boston, MA, USA

4 Program for Autism Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

* These authors have contributed equally to this work

Correspondence to:

Zhiqiang Wang, email:

Yan Ding, email:

Keywords: temporal bone squamous cell carcinoma, recurrent tumor, targeted therapy

Received: November 23, 2016 Accepted: July 18, 2017 Published: July 28, 2017

Abstract

High recurrence rates and poor survival rates for late stage/advanced temporal bone squamous cell carcinoma with the standard treatments continues to be a significant challenge to otolaryngologists. Targeted therapy for temporal bone squamous cell carcinoma after relapse has not been reported. Here we present a 58-year-old man who was diagnosed with recurrent temporal bone squamous cell carcinoma and treated with a regimen developed using whole exome sequencing. Somatic mutations in genes encoding catenin beta 1 and vascular endothelial growth factor receptor 2 were identified in the patient’s tumor sample compared to the normal tissue. The patient was then treated with Bevacizumab in combination with pemetrexed. After two weeks of treatment, tumor volume was reduced by 95% measured by MRI, and the Visual Analogue Scale headache scores went down from 10/10 to 2/10. Our results reveal novel gene mutations of temporal bone squamous cell carcinoma and demonstrate, for the first time, an effective targeted therapy for temporal bone squamous cell carcinoma. The successful treatment regimen of bevacizumab and pemetrexed may provide a new treatment option for treating recurrent temporal bone squamous cell carcinoma that fails to respond to conventional tumor resection, radiotherapy, and/or chemotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19649